Home > Resources > Whitepapers > BREAST CANCER DRUGS FUNDING AND TRIALS

BREAST CANCER DRUGS FUNDING AND TRIALS

August 1, 2017

This white paper arises out of the Pink Ribbon drugs funding & trials conference, held at the faculty of pharmaceutical medicine on 23 March 2017 (full programme provided on page 13-15). The general theme to emerge from the conference is that the UK would benefit from enhanced communication between:
• Pharma, regulators and NICE to expedite drug and pricing approval;
• Regulators, NICE and hospitals to allow hospitals time to prepare for new drugs, for example through horizon scanning, with transparency on costs, efficacy and safety profile;
• Pharma and trials database creators, for example, Cancer Research UK (CRUK), to ensure information on clinical trials is effectively disseminated to those patients who may wish to take part – for the benefit of the patients themselves, as well as the national health service (NHS) and pharma.

Spotlight

SIRO Clinpharm Pvt. Ltd.

SIRO Clinpharm, winner of "Best Clinical Research Company" of the year in Healthcare and Fitness Leadership Awards 2016 organised by CMO Asia and Stars of the Industry Group and two times winner of Frost & Sullivan 'Indian Clinical Research Organization of the year' award, is a drug development solutions provider to the global healthcare industry.

OTHER WHITEPAPERS

2022 Global Life Sciences Outlook

whitePaper | January 3, 2022

While valuations for the life sciences sector in this past year have been mixed, the underlying performance and outlook for the

Unlocking iPSCs to Improve CNS Modeling and Drug Discovery

whitePaper | June 15, 2022

To date, therapeutic advances in treating central nervous system (CNS) disorders have been incremental at best. As the global population increases and older demographics begin to make up a disproportionately larger percentage,

Overcoming Pharma’s Launch Performance Problem

whitePaper | March 24, 2023

The prescription medicine market recovered from the wild swings of the early pandemic with renewed volume growth, driven by generics. COVID-19 vaccines and treatments have created a substantial market.

Expediting early-phasedevelopment ofsmall molecules: Anintegrated approach

whitePaper | November 18, 2022

Small molecule drug development has changed substantially in recent years. With the heightened focus on molecularly targeted therapies, small molecule active pharmaceutical ingredients (APIs).

Prescription Drug Pricing: How Lack of Transparency Reduces Market Access, Utilization, and Adherence

whitePaper | November 25, 2019

It's clear that healthcare prices weigh heavily on the minds of Americans, and the time has come for the pharmaceutical industry to take the reins of the prescription drug pricing dialogue with consumers.

Seize the digital momentum

whitePaper | January 23, 2023

Investments in biopharmaceutical (biopharma) research and development (R&D) continue to fuel innovation and shape the future of health. However, this year’s analysis demonstrates that despite impressive examples of innovative products the step-change in improved productivity seen in 2021 has not continued.

BREAST CANCER DRUGS FUNDING AND TRIALS